Drug Type CAR-NK |
Synonyms- |
Target |
Action modulators, antagonists |
Mechanism CXCR3 modulators(C-X-C motif chemokine receptor 3 modulators), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Esophageal Squamous Cell Carcinoma | Preclinical | - | 27 May 2026 | |
| Non-Small Cell Lung Cancer | Preclinical | - | 27 May 2026 |





